Equities research analysts expect that Zoetis Inc (NYSE:ZTS) will post sales of $1.33 billion for the current quarter, according to Zacks. Three analysts have provided estimates for Zoetis’ earnings. The highest sales estimate is $1.35 billion and the lowest is $1.31 billion. Zoetis posted sales of $1.23 billion during the same quarter last year, which suggests a positive year over year growth rate of 8.1%. The company is scheduled to report its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Zoetis will report full-year sales of $1.33 billion for the current year, with estimates ranging from $5.68 billion to $5.77 billion. For the next year, analysts anticipate that the firm will report sales of $6.03 billion per share, with estimates ranging from $5.90 billion to $6.10 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Zoetis.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.03. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. Zoetis’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.47 earnings per share.
In related news, insider Heidi C. Chen sold 37,453 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total value of $3,034,442.06. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Roxanne Lagano sold 35,663 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the completion of the sale, the executive vice president now owns 49,919 shares in the company, valued at approximately $4,044,437.38. The disclosure for this sale can be found here. Corporate insiders own 0.31% of the company’s stock.
Several hedge funds have recently modified their holdings of the stock. Chemical Bank purchased a new stake in shares of Zoetis in the fourth quarter worth $350,000. Cambridge Investment Research Advisors Inc. raised its position in shares of Zoetis by 27.9% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 17,881 shares of the company’s stock worth $1,288,000 after buying an additional 3,904 shares in the last quarter. Xact Kapitalforvaltning AB raised its position in shares of Zoetis by 9.8% in the fourth quarter. Xact Kapitalforvaltning AB now owns 70,114 shares of the company’s stock worth $5,051,000 after buying an additional 6,253 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Zoetis by 31.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 134,904 shares of the company’s stock worth $9,719,000 after buying an additional 32,149 shares in the last quarter. Finally, Dixon Hubard Feinour & Brown Inc. VA raised its position in shares of Zoetis by 106.2% in the fourth quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 25,090 shares of the company’s stock worth $1,807,000 after buying an additional 12,925 shares in the last quarter. Institutional investors own 94.18% of the company’s stock.
Zoetis (NYSE:ZTS) traded up $2.03 during mid-day trading on Tuesday, hitting $82.79. The stock had a trading volume of 2,662,714 shares, compared to its average volume of 3,080,078. The company has a market capitalization of $39,980.00, a price-to-earnings ratio of 37.98, a PEG ratio of 1.81 and a beta of 1.07. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77. Zoetis has a 52 week low of $52.25 and a 52 week high of $82.93.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be given a dividend of $0.126 per share. The ex-dividend date is Thursday, April 19th. This represents a $0.50 annualized dividend and a dividend yield of 0.61%. Zoetis’s dividend payout ratio is currently 22.94%.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.